
















































Worldwide, the proportion of older and highly aged 
people in the population is rising fast [1]. Metabolic and 
physical health generally decline among older adults, be  
 
 
















































it in a highly heterogeneous fashion [2]. Hence, there is 
an urge to stimulate healthy ageing among the 
increasing group of older adults. Metabolic health can 
successfully be improved by lifestyle changes, such as 
dietary restriction and/or increased physical activity [3-



























adults, however,  it  is not  clear whether  these programs are equally healthy.  In  the Growing Old Together  study, we
applied  a  13‐weeks  lifestyle  program,  with  a  target  of  12.5%  caloric  restriction  and  12.5%  increase  in  energy
expenditure through an increase in physical activity, in 164 older adults (mean age=63.2 years; BMI=23‐35 kg/m2). Mean
weight loss was 4.2% (SE=2.8%) of baseline weight, which is comparable to a previous study in younger adults. Fasting
insulin  levels, however, showed a much smaller decrease  (0.30 mU/L  (SE=3.21)) and a more heterogeneous  response
(range=2.0‐29.6 mU/L). Many other parameters of metabolic health, such as blood pressure, and thyroid, glucose and
lipid metabolism improved significantly. Many 1H‐NMR metabolites changed in a direction previously associated with a
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9], thereby reducing the risk for cardiovascular disease 
(CVD). An example of a lifestyle intervention showing 
this metabolic improvement in young adults (28-45 
years of age) is the CALERIE study, a 6-month lifestyle 
intervention reducing energy balance by 25% in 12 
overweight individuals (body mass index (BMI) 25-30 
kg/m2) [6]. As yet, it is unclear whether a 25% 
reduction in energy balance likewise improves 
metabolic health in older adults and is feasible in this 
age group.  
 
Poor metabolic health is generally marked by high 
levels of total cholesterol, glucose, insulin, triglycerides, 
and blood pressure and low levels of HDL cholesterol, 
free triiodothyronine (fT3), and adiponectin [10-13], 
except in highly aged individuals (above 75 years) 
[14,15]. Remarkably, the majority of parameters of poor 
metabolic health inversely associate with familial 
longevity, as shown by comparison of middle-aged 
offspring of long-lived subjects and their spouses [16-
19]. Besides clinical markers, metabolic health can also 
be monitored by novel technologies, such as Nuclear 
Magnetic Resonance (NMR), which are able to measure 
large numbers of metabolites in an affordable and 
standardized way. Distinct profiles of metabolites have 
been demonstrated to associate with intake of specific 
food components [20,21], (future) type 2 diabetes 
(T2D) [22-24] and CVD [18,25,26], showing the 
potential of metabolomics to monitor metabolic health. 
However, it has not yet been established which optimal 
set of markers monitors the metabolic effects of a 
lifestyle change in older adults.  
 
In the Growing Old TOgether (GOTO) study we 
investigated the effect of a lifestyle intervention in older 
adults by both clinical and metabolomic profiles. 
Participants reduced energy balance by 25% for 13 
weeks, targeted by 12.5% reduction in caloric intake 
and 12.5% increase in physical activity, corresponding 
to one of the three intervention conditions previously 
applied in the CALERIE study [6]. In CALERIE, 12 
participants received this intervention. The GOTO study 
consisted of 164 individuals (mean age 63.2 years) with 
a BMI of 23-35 kg/m2, which are mostly couples of 
whom one was member of a longevity family and the 
other their spouse. Since fasting insulin was one of the 
markers that showed a reduction within three months in 
the CALERIE study [6], this parameter was used as our 
primary outcome. In addition, we measured the 
response to the intervention by other established 
markers of metabolic health, state-of-the-art metabolic 
profiles measured with Hydrogen-1 NMR (1H-NMR), 





Longevity family members and controls are largely 
similar on baseline 
 
Of the 164 individuals who started the intervention 
study, one dropped out prior to completion of the study 
(Fig. 1). A selection of the clinical baseline 
characteristics of the participants according to familial 
background, i.e. longevity family member or control, is 
depicted in Table 1 (complete clinical baseline 
characteristics are provided in Supplementary Table 
1A). Baseline characteristics of 1H-NMR metabolites 
are shown in Supplementary Table 1B. Gender 
differences were observed for many parameters. In 
contrast to the Leiden Longevity Study as a whole, in 
which many metabolic parameters differ significantly 
between longevity family members and controls 
[16,18,19], we observed only few significant 
differences in the parameters at baseline between the 
small groups included in the GOTO study. Therefore, 
we studied the effects of the intervention in both groups 
combined.  
 
Intervention improves body composition and 
metabolic health  
 
The effect of the 13-weeks lifestyle change on clinical 
parameters is depicted in Table 2 and Supplementary 
Table 2A. For the primary outcome, i.e. fasting insulin, 
a minor mean (SE) decrease of 0.30 mU/L (3.21 mU/L) 
and a considerable heterogeneity (range -11.5-10.5 
mU/L) was observed (Supplementary Fig. 1). Measures 
of body composition generally improved, as shown by a 
mean weight loss of 3.3 kg (0.18 kg), i.e. 4.2% (2.8%) 
of baseline weight (Fig. 2), a body fat mass decrease of 
11.7% (8.9%), and a fat free mass decrease of 0.7 kg 
(0.1 kg). Measures of health and functioning showed a 
significant decrease of 4.3 mmHg (1.0 mmHg) in 
systolic and 1.7 mmHg (0.6 mmHg) in diastolic blood 
pressure. We noted that the changes in weight and 
systolic blood pressure (Fig. 3), but not in insulin levels, 
were dependent on baseline levels.  
 
Resting energy expenditure (REE) significantly 
decreased with 49.2 kcal/day (8.0 kcal/day). Hand grip 
strength was not changed by the lifestyle change, but 
physical functioning, mental QoL in women, and the 
Framingham Risk Score improved. The diagnostic 
measures showed a significant decrease in total and 
LDL cholesterol, HDL cholesterol in women, fT3, and 
















































Plasma metabolite profile changes due to 3 months 
lifestyle intervention  
 
To determine the overall effect of the intervention on the 
1H-NMR metabolites, we performed Principle 
Component Analysis. This analysis indicated that a major 
part of the variation in the metabolites (PC1, explaining 
32.4% of the total variance) could be attributed to the 
effects of the lifestyle intervention (Fig. 4). As shown in 
Supplementary Fig. 2, the intervention effect, as 
represented by PC1, coincides with many of the 
measured 1H-NMR metabolites. The effects of the 











































blood are depicted in Fig. 5 and Supplementary Table 
2B. Multiple amino acids levels changed significantly 
and include a decrease of the branched-chain amino acid 
leucine and the aromatic amino acid tyrosine. In addition, 
the levels of multiple glycolysis-related metabolites, 
ketone bodies, fatty acids, metabolites involved in fluid 
balance and inflammation, apolipoproteins, lipid 
concentrations, and lipoprotein particle sizes showed a 
significant decrease. Citrate levels, large HDL cholesterol 
concentrations, and HDL particle size, on the other hand, 
increased after the lifestyle change. For several HDL-
related metabolites we observed an opposite effect of the 
intervention in men and women. 
Figure 1. Flow chart of participants in the trial. 
  


















































Effects of lifestyle intervention at old age (partly) 
independent of weight loss 
 
To investigate whether the observed response mainly 
coincides with the change in weight, we adjusted for 
weight loss. For most of the parameters of health and 

















































metabolites, adjustment for weight loss reduced the 
effects of the intervention. However, the changes in fT3, 
total, VLDL, LDL, and IDL cholesterol, as well as those 
in phosphoglycerides, cholines, sphingomyelines, and 
some glycolysis intermediates, remained largely 
unchanged after this adjustment (Table 2, Supplementary 




Characteristic   n Longevity family members n Controls 
 Women, n (%) 39 (43.3) 42 (56.8) 
  Age, mean (SD) [range], years 90 63.4 (5.4) [49.1-75.1] 74 62.4 (6.1) [46.7-73.5] 
Body composition, mean (SD) [range] 
  Weight, kg 89 79.8 (9.6) [62.5-105.7] 73 79.0 (10.2) [60.5-102.4] 
Men 50 84.3 (8.0) [67.2-105.7] 31 85.4 (8.1) [70.1-102.4] 
Women 39 74.1 (8.4) [62.5-95.4] 42 74.1 (8.9) [60.5-100.4] 
  BMI, kg/m2 89 27.0 (2.6) [22.9-34.2] 73 26.9 (2.4) [22.9-33.5] 
  Waist circumference, cm 90 96.2 (7.9) [74-122] 74 96.1 (8.2) [77-112] 
Men 51 98.1 (7.4) [80-122] 32 100.1 (6.4) [89-112] 
Women 39 93.6 (7.9) [74-112] 42 93.0 (8.1) [77-111] 
Health and functioning, mean (SD) [range]  
  Systolic blood pressure, mm Hga 65 135.4 (15.9) [111-196] 48 137.8 (17.1) [101-173] 
  Diastolic blood pressure, mm Hga 65 83.5 (7.4) [64-101] 48 84.7 (9.2) [65-108] 
Medication use, n (%) 
  Lipid-lowering agent 90 11 (12.2) 74 18 (24.3) 
  Antihypertensive agent 90 23 (25.6) 74 26 (35.1) 
Diagnostic measurements, mean (SD) [range]  
 Fasting glucose, mmol/L 90 5.0 (0.5) [3.6-6.5] 74 5.0 (0.6) [4.0-7.6] 
  Fasting insulin, mU/Lb 90 9.4 (5.1) [2.0-29.6] 74 9.0 (3.9) [2.0-22.6] 
  HOMA-IR 88 1.2 (0.6) [0.4-3.8] 72 1.2 (0.5) [0.4-2.7] 
  Total cholesterol, mmol/Lc 79 5.5 (1.0) [3.3-8.6] 56 5.5 (1.0) [3.2-8.0] 
 HDL cholesterol, mmol/Lc 79 1.6 (0.4) [0.6-3.1] 56 1.4 (0.4) [0.6-2.3] 
Men 43 1.4 (0.3) [1.0-2.0] 23 1.1 (0.2) [0.6-1.6] 
Women 36 1.7 (0.5) [0.6-3.1] 33 1.6 (0.3) [1.2-2.3] 
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Finally, the beneficial effects on physical functioning and 
mental QoL in women were also largely independent of 





















































Hence, the effect of the lifestyle change on many of the 
metabolic parameters and well-being in this study occurs 




















































Characteristic, mean (SE)   n Difference P-valuea 
Body composition         
  Weight, kg   161 -3.34 (0.18) <0.001 
  Men 80 -3.42 (0.27) <0.001 
  Women 81 -3.25 (0.23) <0.001 
  BMI, kg/m2   161 -1.13 (0.06) <0.001 
  Waist circumference, cm   163 -4.3 (0.4) <0.001 
  Men 82 -4.4 (0.6) <0.001 
  Women 81 -4.2 (0.6) <0.001 
  Body fat, %   161 -2.26 (0.16) <0.001 
  Men 80 -2.22 (0.23) <0.001 
  Women 81 -2.29 (0.21) <0.001 
  Fat free mass, kg2   161 -0.67 (0.10) <0.001 
  Men 80 -0.83 (0.16) <0.001 
  Women 81 -0.51 (0.13) <0.001 
Health and functioning         
  Systolic blood pressure, mm Hgb   113 -4.33 (0.98) <0.001* 
  Diastolic blood pressure, mm Hgb   113 -1.66 (0.61) 0.007 
  REE, kcal/day   126 -49.2 (8.0) <0.001* 
  Men 65 -46.59 (11.76) <0.001 
  Women 61 -51.94 (10.79) <0.001* 
  Handgrip strength, kg   153 0.38 (0.32) 0.25 
  Men 76 0.24 (0.53) 0.65 
  Women 77 0.51 (0.38) 0.18 
  Physical functioning   159 0.14 (0.05) 0.008* 
  Physical quality of life   157 -0.18 (0.61) 0.77 
  Men 82 -0.72 (0.83) 0.39 
  Women 75 0.42 (0.92) 0.65 
  Mental quality of life   157 0.9 (0.70) 0.19 
  Men 82 -1.13 (0.84) 0.18 
  Women 75 3.13 (1.12) 0.005* 
  FRS, %   163 -0.51 (0.23) 0.03 
  Men 82 -0.65 (0.43) 0.13 
  Women 81 -0.37 (0.15) 0.01 
 
  








































































































Characteristic, mean (SE)   n Difference P-valuea 
Diagnostic measurements         
  Fasting glucose, mmol/L   163 -0.06 (0.04) 0.16 
  Fasting insulin, mU/Lc   163 -0.05 (0.03) 0.04 
  HOMA-IR   153 -0.03 (0.03) 0.33 
  Total cholesterol, mmol/Ld   135 -0.29 (0.06) <0.001# 
  HDL cholesterol, mmol/Ld   135 -0.01 (0.02) 0.49 
  Men 66 0.04 (0.02) 0.11 
  Women 69 -0.06 (0.03) 0.02* 
  LDL cholesterol, mmol/Ld   135 -0.26 (0.05) <0.001# 
  Triglycerides, mmol/Lc,d   135 -0.04 (0.03) 0.11 
  fT3, pmol/L   163 -0.14 (0.03) <0.001# 
  fT4, pmol/L   163 -0.07 (0.09) 0.44 
  TSH, mU/Ld   163 -0.04 (0.03) 0.17 
  DHEAS, nmol/Lc   163 -0.02 (0.01) 0.20 
  Men 82 -0.01 (0.02) 0.47 
  Women 81 -0.02 (0.02) 0.28 
  Leptin, µg/Lc   163 -0.26 (0.03) <0.001* 
  Men 82 -0.29 (0.04) <0.001* 
  Women 81 -0.23 (0.03) <0.001* 
  Adiponectin, mg/Lb   163 0.04 (0.01) 0.005 
  Men 82 0.09 (0.02) <0.001 
  Women 81 -0.01 (0.02) 0.76 
  IGF-1, nmol/L   163 0.10 (0.24) 0.67 
  Men 82 0.36 (0.31) 0.24 
  Women 81 -0.17 (0.35) 0.64 
  IGFBP-3, mg/L   163 -0.05 (0.05) 0.37 
  IGF-1:IGFBP-3   163 0.004 (0.003) 0.21 
  Men 82 0.009 (0.006) 0.14 
  Women 81 -0.001 (0.003) 0.82 






Parameters were analysed  separately  in men and women  if  there was a  significant gender‐difference at 
baseline. BMI, body mass  index; REE,  resting energy expenditure; FRS, Framingham  risk score; HOMA‐IR, 
homeostatic  model  assessment  ‐  insulin  resistance;  HDL,  high  density  lipoprotein;  LDL,  low  density 
lipoprotein;  fT3,  free  triiodothyronine;  fT4,  free  thyroxine;  TSH,  thyroid  stimulating  hormone;  DHEAS, 
dehydroepiandrosterone‐sulfate;  IGF‐1,  insulin‐like  growth  factor  1;  IGFBP‐3,  insulin‐like  growth  factor 
binding protein 3; CRP, C‐reactive protein. 
  










































































































































A 13-weeks lifestyle change among older adults aimed 
at combining 12.5 % decreased energy intake and 
12.5% increased physical activity improved parameters 
of body composition, relevant clinical markers, such as 
fasting insulin, our primary endpoint, blood pressure, 
glucose, lipid and thyroid metabolism, and 1H-NMR 
metabolites. In addition, physical functioning and 
mental QoL in women improved. For most of the 
parameters, the improvements were, at least partly, 
independent of weight loss, indicating that we 
monitored aspects of metabolic health additional to 
weight loss. 
 
The GOTO study shows that one of the intervention 
conditions previously pioneered by the CALERIE study 
in younger and more overweight subjects [6] seems 
generally feasible, since only one drop-out was 
observed and metabolic health was generally improved. 
The older adults in GOTO generally lost weight during 
the intervention and the mean change in weight was 
comparable to CALERIE. The mean change in fasting 
insulin, however, was much smaller in GOTO (0.30 
mU/L) than in CALERIE (2.06 mU/L) and the 
heterogeneity in response was much larger (range -
11.5 – 10.5 mU/L and -8 – 2 mU/L, respectively). 
There could be several explanations for this difference. 
First, the sample size of the GOTO study is almost 14 
times as large as the ‘calorie restriction with exercise’ 
study group in CALERIE and may have estimated the 
effect of the intervention more accurately. Second, the 
baseline and response variation in insulin and other 
metabolic variables was larger in GOTO than in 
CALERIE, which might be caused by the higher mean 
age of our population (mean age 63 years (GOTO) 
versus 39 years (CALERIE)) and broader range in 
baseline BMI. Third, because the intervention in 
GOTO was less controlled, the outcome was likely 
more heterogeneous. Heterogeneous responses to 
lifestyle interventions should be further explored and 
carefully monitored in even larger studies of older 
adults. 
 
The potential improvement of metabolic health is 
reflected in the change of clinical parameters as well as 
metabolites. The observed decrease in leucine, tyrosine, 
glucose, pyruvate, glycerol, total fatty acids, 
monounsaturated fatty acids, α-acid glycoprotein, lipid 
concentrations, and VLDL particle size and increase in 
fatty acid chain length and citrate imply a decreased 
future CVD risk based on a previous prospective study, 
including older adults, using the same 1H-NMR assay 
[26]. This would correspond with reduced FRS in 
women after the lifestyle change. In addition, the 
observed decrease in leucine, tyrosine, glucose, 3-
hydroxybutyrate, and creatinine and increase in glycine 
is considered beneficial with respect to (risk of) T2D 
[22-24]. The observed gender difference in HDL 
metabolites in response to the intervention may be due 
to the fact that women already displayed more 
beneficial levels at baseline as compared to men, while 
the observed decrease in HDL metabolites in men may 
be caused by a decrease in alcohol intake [27]. 
 
Unlike insulin, blood pressure levels, and the 
Framingham Risk Score, parameters indicative of lipid 
and thyroid metabolism, as well as several 1H-NMR 
metabolites, changed largely independent of the 
reduction in body weight. Such changes may point at 
the occurrence of metabolic shifts in response to dietary 
changes and increase in physical activity, exemplified 
by decreased fT3 levels, which were also observed in 
the CALERIE study after 3 months [6]. Basically, our 
data suggest that the effects of the intervention on 
metabolic health can be monitored by a combination of 
weight, fT3 levels, and a single 1H-NMR metabolite 
assay.  
 
Figure  4.  Effect  of  age,  gender,  and  intervention  on  1H‐NMR
metabolite‐based PC’s. The colour of  the blocks  represents  the
magnitude  of  the  effect,  while  the  P‐value  is  mentioned
between brackets. 
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Next to metabolic health, we observed an improvement 
of mental health status in women, which was 
independent of weight loss. The positive effect of social 
interaction by participating in a trial may underlay this 
improvement. However, physical activity has also been 
described to improve mental health [28,29]. This effect 
was not observed in men, which may be explained by 
their better mental health at baseline. Mental health 
improvements may stimulate compliance to a lifestyle 
change over time. In our study, an additional 
questionnaire showed that 66% of the participants 
indicated that they maintained their new lifestyle one 
year after the intervention, possibly contributed by a 
‘buddy’ effect for these older adult couples. 
 
In conclusion, reducing energy balance by 25% for 13 
weeks by a modest change in dietary habits and 
physical exercise seemed generally feasible in older 
adults (mean age 63 years) and resulted in a weight 
change comparable to younger adults. Despite a 
considerable heterogeneity in response, metabolic 
health was generally beneficially influenced, as 
reflected by most markers of body composition, blood 
pressure, physical functioning, glucose, lipid, and 
thyroid metabolism, and a range of metabolites that 
could be measured with a well-standardized 1H-NMR 
assay. We conclude that monitoring of the response to 
an intervention among elderly is optimized by applying 
metabolomics assays in addition to clinical markers of 
metabolic health. The response to the lifestyle 
intervention applied in GOTO, as measured by 
metabolomics profiles and parameters of wellbeing, can 
be used as reference for more specific dietary 




Study population. Participants for the GOTO study were 
recruited from the Leiden Longevity Study (LLS), a 
longitudinal cohort consisting of 421 families of long-
lived Caucasian siblings, together with their offspring 
and the partners thereof [31]. For the current 
intervention couples consisting of offspring from the 
long-lived siblings and their current partners were 
included. In case one of the two was not eligible to 
participate, single offspring or controls were included to 
obtain the required sample size. Individuals of ages 
between 46 and 75 years and having a BMI ≥23 ≤35 
kg/m2 were recruited between February and October 
2012. Potential participants underwent a telephonic 
screening and a screenings home visit. Exclusion 
criteria were: type I or type II diabetes (on diabetic 
medication); fasting blood glucose level ≥7.0 mmol/L; 
weight change ≥3 kg over the past 6 months; 
engagement in heavy/intensive physical activity (top 
sport or physically heavy work); any disease or 
condition that seriously affects body weight and/or body 
composition including active types of cancer; heart 
failure (NYHA III/VI), COPD (GOLD III/VI); recent 
(<3 months prior to intervention) immobilisation for >1 
week; psychiatric or behavioural problems; use of 
thyroid medication, immunosuppressive drugs (e.g. 
prednisone, methotrexate, biologicals (TNF-alpha 
antagonists); concurrent participation in any other 
intervention study or weight management program, or 
not having a general practitioner. The Medical Ethical 
Committee of the Leiden University Medical Center 
approved the study and all participants signed written 
informed consent. All experiments were performed in 
accordance with relevant and approved guidelines and 
regulations. This trial was registered at the Dutch Trial 
Register (http://www.trialregister.nl) as NTR3499. 
 
Intervention. The intervention comprised 13 weeks of 
25% lowered energy balance by 12.5% reduction in 
energy intake and 12.5% increase in physical activity. 
Baseline energy intake and expenditure were assessed by 
an online version of a 150-item food frequency 
questionnaire (FFQ) [32] and by the International 
Physical Activity Questionnaire- Short Form (IPAQ-SF) 
[33]. The IPAQ-SF collects information on time spent 
walking, in moderate and vigorous physical activity, and 
sitting over the last seven days to estimate the total 
metabolic equivalent (MET) in minutes per week.  
 
Individual guidelines were prescribed by respectively a 
dietician and physiotherapist in consultation with the 
participant to match the subjects’ preferences and 
physical capabilities. The dietary guidelines were as 
much as possible according to the ‘Dutch Guidelines for 
a healthy diet’ [34]. Participants were advised to 
increase the amount of physical activity in such a way it 
fitted in their daily life pattern, as couple or alone, by 
walking, cycling, adjusted activities in and around the 
house and participation in local sport activities and 
facilities. 
  
During the intervention participants had weekly contact 
with the dietician and physiotherapist by phone, email 
or at the participants home (alternating schedule) to 
check and stimulate adherence to the intervention and to 
discuss practical problems and solutions. To optimally 
guide the participants, both dietician and 
physiotherapist combined elements from the Attitude, 
Social influence and self-Efficacy model (ASE) [35], 
the Stages of Change Model [36] and Motivational 
Interviewing [37].  
 
Participants daily recorded their eating behaviour and 
physical activity in a diary. To quantitatively assess 
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dietary intake two telephonic 24-h recalls were 
performed during the first month and two during the last 
month of the intervention. Days of the recall were 
unannounced to the participant and randomized to 
obtain a good distribution of the different days of the 
week, including weekend days. During the monthly 
home visits body weight and body composition were 
measured. To quantitatively determine physical activity 
prior to the intervention and at the end of the 
intervention accelerometers worn at home during seven 
days on wrist and ankle (GENEActiv, Activinsights, 
Kimbolton, UK) were used.  
 
Anthropometrics. Height and weight were measured to 
the nearest 0.1 cm and 0.1 kg, respectively (Seca Clara 
803, Seca Deutschland, Hamburg, Germany), with the 
person dressed in light clothing and without shoes. 
Waist circumference was measured to the nearest cm at 
the midpoint between the lowest rib and the top of the 
iliac crest with a non-elastic tape in standing position 
without shoes. Fat free mass and fat mass were 
measured using the In-Body 720 body composition 
analyser (Biospace, Cerritos, CA, USA). 
 
Blood pressure. Trained staff members measured blood 
pressure in sitting position after a 10-minute rest on the 
dominant arm using a validated blood pressure device 
(Maxi-Stabil 3, Welch Allyn, Leiden, the Netherlands). 
Blood pressure was measured 4 times, twice in the first 
part of the afternoon and twice at the end of the 
afternoon. Systolic and diastolic blood pressures were 
calculated as the average of the four measurements. 
 
Energy metabolism. Resting metabolic rate was 
measured 65 minutes after a standardized meal by 
indirect calorimetry, using a ventilated hood system 
(Care Fusion Canopy Jaeger Oxycon Pro, CareFusion 
Germany, Hoechberg, Germany). The standardized 
meal was 500 kcal and consisted of one raisin bun, one 
whole-wheat bun with margarine and 20 grams of 
Gouda cheese and a cup of tea without milk or sugar. 
Participants were lying on a bed under the ventilated 
hood in a quiet, temperature controlled room for 30 
minutes. The initial 5 minutes of the measurement were 
not used for the analysis. VO2 and VCO2 were 
measured every minute. Resting energy expenditure 
(REE) and respiratory quotient (RQ) were calculated 
using the formulas: 
 
REE= 3.91 VO2 + 1.10 VCO2 – 1.93N.  
RQ = VCO2 / VO2 
 
To exclude outliers in energy expenditure, the degree of 
variation based on the coefficient of variation (CV) was 
examined based on the mean and the SD of five data 
points that were used. Data per 5 consecutive minutes 
was included if the RQ data over these 5 minutes had a 
CV <5%. 
 
Physical performance. Physical performance was 
assessed by the short physical performance battery 
(SPPB), which consisted of three components: balance, 
gait speed, and chair rise ability [38]. Handgrip strength 
was determined by three consecutive measures using a 
hand dynamometer (Jamar, Lafayette Instrument, 
Lafayette, IN, USA) at both hands. 
 
Quality of life. Quality of life was assessed using the 
Short Form Health Survey-12 (SF-12). This 
questionnaire [39] distinguishes physical and mental 
health, each assessed by six items.  
 
Framingham risk score. The Framingham risk score 
(FRS), which estimates the 10-year risk for developing 
coronary heart disease, was calculated using the criteria 
proposed by the Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults 
[40]. The score is based on the age, gender, total and 
HDL cholesterol serum level, smoking status, and 
systolic blood pressure of an individual. 
 
Diagnostic measurements. All measurements were 
performed in fasted serum collected by venipuncture. 
Cholesterol, free thyroxine (fT4), glucose, high-density 
lipoprotein (HDL) cholesterol, triglycerides, high-
sensitivity C-reactive protein (hsCRP), and thyroid 
stimulating hormone (TSH) were measured on the 
Roche/Hitachi Modular P800 analyzer (Roche 
Diagnostics, Almere, The Netherlands). Dehydro-
epiandrosterone sulfate (DHEAS), insulin, insulin-like 
growth factor 1 (IGF-1), and insulin-like growth factor 1 
binding protein 3 (IGF-BP3) were assessed on the 
Immulite 2000 XPi (Siemens, Eschborn, Germany). 
Adiponectin and leptin were determined using Human 
Adiponectin and Leptin RIA kits (EMD Millipore 
Corporation, Billerica, MA, USA). Free triiodothyronine 
(fT3) was determined using the ARCHITECT Free T3 
assays (Abbott Laboratories, Abbott Park, IL, USA) on 
the Hitachi Modular E170 analyzer (Roche Diagnostics). 
Coefficients of variation for all laboratory analyses were 
<8%. Low-density lipoprotein (LDL) cholesterol was 
calculated using the Friedewald formula [41], while the 
homeostasis model assessment-estimated insulin 
resistance (HOMA-IR) was calculated using the 
publically available HOMA calculator 
(https://www.dtu.ox.ac.uk/homacalculator) [42]. 
 
Hydrogen-1 Nuclear Magnetic Resonance metabolites. 
1H-NMR metabolites were measured using a previously 
described platform [43]. For our analysis we used the 
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total lipid concentrations, fatty acid composition, and 
low-molecular-weight metabolites, including amino 
acids, glycolysis-related metabolites, ketone bodies and 
metabolites involved in fluid balance and immunity. All 
metabolite concentrations were natural log-transformed 
and scaled to standard deviation units before analysis. 
 
Statistical analysis. Baseline differences between 
longevity family members and controls were calculated 
using a linear mixed model adjusted for age, gender 
(fixed effects), and household (random effects). The 
effects of the intervention were determined using a 
linear mixed model adjusted for age, gender, status 
(longevity family member or control) (fixed effects), 
household, and individual (random effects). Parameters 
were analyzed separately in men and women if there 
was a significant gender-difference at baseline. For 
additional analyses, weight was added to the model to 
determine weight loss-independent effects.  
 
Principle Component Analyses and the following 
association analyses with age, gender and intervention 
were performed in R [44]. Principle Components (PCs) 
were computed using the function prcomp of the stats 
package [44]. Association analyses with the obtained 
PCs were performed using mixed linear models, 
function lmer, of package lmerTest [45]. Heatmaps 
were drawn to visualize the magnitude of the statistics 
from the association analyses using labeledHeatmap of 
the WGCNA package [46]. 
 
Sample size calculation was based on fasting insulin as 
primary end point, whereby we assumed a decrease of 
21% (9.75 to 7.69 µIU/mL), since this was observed 
after 3 months in the calorie restriction with exercise 
group of the CALERIE study [6], which is comparable 
to our study. As the mean fasting insulin levels 
(µIU/mL) in longevity family members and controls in 
the complete LLS cohort were 6.93 (SD=4.3) and 8.70 
(SD=6.6), respectively, and a correlation of 0.6 between 
repeated insulin measurements was assumed [47], we 
based our power calculation on an expected mean 
decrease of 1.65 µIU/mL, SD 4.9. With a power of 80% 
and an α of 5% this translates in a required sample size 
of 72 individuals. In a recent large meta-analysis, 
genetic background did not influence the association of 
healthy diet with fasting glucose or insulin [48]. 
Nevertheless, we doubled the sample size of our study 
to account for potential differences between longevity 
family members and controls in response to the 
intervention. Taking into account a dropout rate of 10%, 
we aimed to include 80 couples in the intervention. 
  
All statistical analyses were performed with STATA⁄SE 
11.2 (StataCorp LP, College Station, TX, USA) and 
SPSS Statistics v20 (IBM Corp, Armonk, NY, USA) 
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